[{"id":"942a4b1b-75eb-4eb8-9957-11d7427ae86e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03195699","created_at":"2021-01-18T15:45:29.539Z","updated_at":"2024-07-02T16:35:10.349Z","phase":"Phase 1","brief_title":"Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers","source_id_and_acronym":"NCT03195699","lead_sponsor":"Tvardi Therapeutics, Incorporated","biomarkers":" PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TTI-101 oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/15/2017","start_date":" 11/15/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-10"}]